Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil
December 06, 2021 14:41 ET
|
Sorrento Therapeutics, Inc.
Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX™ COVID-19 Virus Rapid Antigen Detection Test in Brazil. SAN...
Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination
December 06, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business...
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
December 05, 2021 14:28 ET
|
Sorrento Therapeutics, Inc.
A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity.Other analogs of the series have been evaluated...
Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference
November 30, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”
November 29, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for...
Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
November 22, 2021 14:53 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a...
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
November 12, 2021 15:19 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX...
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
November 12, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR and Bruton’s tyrosine kinase (BTK) in advanced NSCLC patients...
Sorrento Awarded California Competes Tax Credit
November 07, 2021 13:08 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California...
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
November 03, 2021 10:06 ET
|
Sorrento Therapeutics, Inc.
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with...